Free Pulmonology CME

  • FREE

    Frontiers in the treatment of systemic sclerosis interstitial lung disease: therapeutic updates and best practices

    In this online CME self-learning program: Systemic sclerosis (SSc) is a rare connective tissue disease that affects between eight and 56 people per million per year and up to 341 people per million total in the U.S., of whom around 70% will experience interstitial lung disease (ILD). The disease is characterized by a progressive course of scarring to the blood vessels underlying the skin, connective tissue, joints, and organs. The pathology of SSc remains to be fully elucidated, but different immunologic and genetic pathways have been explored as potential precipitating factors for SSc. Based on what is known, SSc-ILD may be summarized into three steps: 1) continuous injury to endothelial cells, 2) activation of innate and adaptive immunity, 3) recruitment and activation of fibroblasts. Early diagnosis is crucial for preservation and survival of major organs. Lung fibrosis is considered irreversible, and if the disease has progressed far beyond repair, lung transplantation is considered. Therefore, early detection is paramount in order for patients to preserve their lung function.

    Target Audience:

    The following HCPs: pulmonologists, rheumatologists, radiologists, primary care physicians, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with SSc-ILD.

    By the end of the session the participant will be able to:

    • Define the clinical features of systemic sclerosis
    • Discuss current understanding of the biology of systemic sclerosis
    • Define clinical phenotypes of systemic sclerosis
    • Explore pulmonary manifestations of systemic sclerosis
    • Understand the approach to diagnosis of systemic sclerosis interstitial lung disease and other pulmonary manifestations
    • See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/08/2020
    • Expiration of CME credit: 10/08/2022
  • FREE

    Cystic fibrosis: Therapeutic updates and optimizing treatment

    Cystic Fibrosis (CF) is a genetic disease that affects nearly 70,000 people worldwide with more than 90% of patients diagnosed of Caucasian descent and a median lifetime survival remains a mere 43.6 years. CF is caused by an autosomal recessive mutation in the CF transmembrane regulator (CFTR) gene, which controls the other chloride and sodium channels at the cell surface and is found in the lungs, liver, pancreas, intestine, sweat duct, and epididymis. The primary organs in which the disease manifests clinically are the pancreas, leading to malabsorption of nutrients, and the lungs due to the accumulation of thick, sticky mucous that contributes to airway obstruction. CF causes several clinical complications, including recurrent pulmonary infections, nasal polyps, CF-related diabetes, fat-soluble vitamin deficiencies, acid reflux, and liver failure.

    Target Audience:

    The following HCPs: pulmonologists, pediatricians, gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with CF.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of CF such that it might inform treatment mechanisms.
    • Identify the currently available and emerging pharmacotherapeutic treatments for the management of CF and apply them to patient cases using evidence-based medicine.
    • Describe newly approved and investigational therapies in development for CF.
    • Evaluate an ongoing treatment plan for a specific patient with CF to optimize safety and efficacy, suggesting modifications for improvement, including the management of complications.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/18/2020
    • Expiration of CME credit: 07/18/2022
  • FREE

    Alpha-1 antitrypsin deficiency (AATD): Optimizing pharmacotherapeutic management strategies

    Alpha 1-antitrypsin deficiency (AATD), characterized by low serum levels of the serine protease inhibitor alpha-1 antitrypsin (AAT), is a genetic disorder resulting in destruction of lung structures. Reduced levels of AAT result in overactivity of neutrophil elastase, which destroys connective tissue within the lung and causes degradation of alveoli, reduced pulmonary elastic recoil, and airflow. Breakdown of the alveoli eventually manifest as emphysema or other forms of chronic lung disease, including chronic obstructive lung disease (COPD). Other complications associated with AATD include liver disease, panniculitis, and vasculitis. The most common cause of death in patients with severe AATD is respiratory failure, which accounts for 45 to 72% of deaths. Smoking, occupational hazards such as firefighting, and high levels of cumulative exposure to pollution accelerate the rate of lung function decline in people with AATD. AATD is estimated to affect one out of every 2,000 to 5,000 individuals, mainly of North European or Iberian ancestry, with a global prevalence of over 3.4 million affected individuals.

    Target Audience:

    The following healthcare professionals: pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.

    By the end of the session the participant will be able to:

    • Summarize the present state of awareness of AATD among healthcare professionals and its attendant impact on patient care.
    • Describe the best time to test a patient for AATD and whether to conduct a family screening.
    • Apply best treatment practices to patients with AATD in various clinical scenarios.
    • Describe the challenges associated with the optimal diagnosis and treatment of AATD.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/26/2020
    • Expiration of CME credit: 07/26/2022
  • FREE

    Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies

    Interstitial lung disease (ILD) is a collective term used to categorize more than 200 different types of diseases that affect the alveolar structures, the pulmonary interstitium, and small airways.

    After completing Interstitial Lung Disease with Progressive Lung Disease Phenotype (ILD-PF): Therapeutic Updates, Best Practices, and Emerging Therapies you will be able to:

    • Describe the pathophysiology of and risk factors for ILD-PF such that it might inform treatment mechanisms and strategies
    • Identify signs and symptoms of ILD-PF (e.g., rheumatoid arthritis, chronic hypersensitivity pneumonitis, unclassified ILD)
    • Describe the prevalence, morbidity, and mortality, burden of illness associated with ILD-PF and, conversely, the benefits associated with early identification and treatment
    • Describe current treatment standards and monitoring parameters (HRCT, PFTs) of ILD-PF, including developments in clinical research and treatment guidelines, and apply them to patient cases
    • Discuss ways to improve clinician communication with their patients, including disease education

     

    Target Audience: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with ILD-Pf.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: January 27, 2019
    • Expiration of CME credit: January 27, 2021
  • FREE

    Pilot for Pulmonary COPD Expert Interviews

    Pilot for Pilot for Pulmonary COPD Expert Interviews reviews topics including:
    • What is the 2017 GOLD standard for managing patients with COPD?
    • Stepping up or stepping down – which direction for COPD patients?
    • Is the delivery system a good match for your patients with COPD?

    After completing the Pilot for Pilot for Pulmonary COPD Expert Interviews, you should be better able to:
    • Examine the data and expert recommendations concerning the use of ICS in patients with COPD
    • Evaluate data on the use of single and combination bronchodilators in patents with COPD
    • Discuss clinical scenarios where ICS should or should not be considered

    Target Audiences:
    Pulmonologists, critical care clinicians and other healthcare professionals involved in the management of patients with COPD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: The France Foundation
    • Format: On-Demand Online
    • Material last updated: May 31, 2017
    • Expiration of CME credit: May 31, 2018